市場調查報告書
商品編碼
1426944
MRI 造影劑市場- 副產品(細胞外製劑{離子、非離子}、肝膽製劑)、類型(品牌、學名藥)、應用(神經、肌肉骨骼、心血管、癌症)、最終用途-全球預測,2024- 2032 年MRI Contrast Media Market - By Product (Extracellular Agents {Ionic, Non-ionic}, Hepatobiliary Agents), Type (Branded, Generics), Application (Neurological, Musculoskeletal, Cardiovascular, Cancer), End-use- Global Forecast, 2024-2032 |
由於醫療保健系統對先進影像技術的嚴重依賴,預計 2024 年至 2032 年全球 MRI 造影劑市場將以 4.6% 的CAGR成長。
根據世界衛生組織 2023 年的報告,非傳染性疾病 (NCD) 佔全球死亡人數的 74%,每年奪走 4,100 萬人的生命。其中,1,700萬人在70歲前死於非傳染性疾病,其中86%的過早死亡發生在低收入和中等收入國家。全球與生活方式相關的疾病(例如糖尿病和肥胖症)的增加導致需要診斷成像的疾病的發生率更高。 MRI 造影劑在檢測和監測這些疾病方面發揮著至關重要的作用,提供對內臟器官進展和影響的非侵入性見解。此外,增加對醫療基礎設施的投資,特別是在新興經濟體,正在為採用最先進的醫療設施創造有利的環境。
全球 MRI 造影劑產業根據產品、類型、應用和地區進行分類。
由於其在 MRI 掃描過程中增強血管和心血管結構可視性的作用,血池劑領域預計將在 2032 年獲得牽引力。隨著新型配方的引入,顯著的進步提高了成像品質並減少了副作用,有利於血池劑的採用。這使得特定器官或組織的精確成像成為可能,從而提高了診斷準確性。
學名藥市場預計將在研究期間強勁成長,因為它為醫療保健提供者和患者提供了具有成本效益的替代方案。學名藥的成本效益和可比較的功效正在推動它們的採用,特別是在醫療保健預算受到嚴格審查的地區。此外,持續的產品創新預計將推動產業成長。
在慢性病盛行率不斷上升以及醫療基礎設施投資不斷增加的推動下,亞太地區 MRI 造影劑市場預計在 2024 年至 2032 年期間持續成長。中國和印度等國家正在經歷快速的城市化和不斷成長的中產階級人口,導致醫療保健支出增加。此外,支持性的監管框架和持續的研發努力正在促進先進醫學影像技術在該地區的採用。
The global MRI contrast media market is expected to grow at a CAGR of 4.6% during 2024-2032, driven by the heavy reliance of healthcare systems on advanced imaging technologies.
According to a report by WHO in 2023, noncommunicable diseases (NCDs) account for 74% of global deaths, claiming 41 million lives annually. Of these, 17 million people die from NCDs before the age of 70, with 86% of premature deaths occurring in low- and middle-income countries. The global increase in lifestyle-related diseases, such as diabetes and obesity, contributes to a higher incidence of conditions that necessitate diagnostic imaging. MRI contrast media plays a vital role in detecting and monitoring these diseases, offering non-invasive insights into the progression and impact on internal organs. Moreover, increasing investments in healthcare infrastructure, particularly in emerging economies, are creating a conducive environment for the adoption of state-of-the art medical facilities.
The global MRI contrast media industry is classified based on product, type, application, and region.
The blood-pool agent segment is set to gain traction through 2032, driven by its role in enhancing the visibility of blood vessels and cardiovascular structures during MRI scans. The significant advancements, with the introduction of novel formulations that offer improved imaging quality and reduced side effects are favoring adoption of blood-pool agent. This has enabled the precise imaging of specific organs or tissues, thereby enhancing diagnostic accuracy.
The generics segment is anticipated to grow robustly during the study period as it provides cost-effective alternative to healthcare providers and patients. The cost-effectiveness and comparable efficacy of generic products are driving their adoption, especially in regions where healthcare budgets are under scrutiny. Moreover, continuous product innovation is expected to propel industry growth.
Asia Pacific MRI contrast media market is poised to grow continuously during 2024-2032, driven by the increasing prevalence of chronic diseases, coupled with rising healthcare infrastructure investments. Countries such as China and India are witnessing rapid urbanization and a growing middle-class population, contributing to increased healthcare spending. Additionally, supportive regulatory frameworks and constant R&D efforts are fostering the adoption of advanced medical imaging technologies in the region.